Contact Information: Contact: Investor Relations Andrew Barwicki 516.662.9461 Website: www.nanologix.net
NanoLogix Files a Provisional Patent Application for Treatment of Leukemia
| Source: NanoLogix
SHARON, PA -- (MARKET WIRE) -- March 13, 2007 -- NanoLogix, Inc. (PINKSHEETS : NNLX ) announced
today that it has filed a provisional patent application with the U.S.
Patent Office entitled "A Hydrophobic Hydrocarbon Coated Filtering Device
for the Induction of Apoptosis in Leukemic Cells and Related Methods of
Treating a Patient." This intellectual property application was filed by
the Pittsburgh law firm of Eckert, Seamans, Cherin and Mellott, LLC. The
invention describes a number of unique and innovative methods for killing
leukemia cells outside of a patient's body by dialyzing, irradiating and
biothermically manipulating the cancer cells, thereby killing the leukemia
cells extracorporeally in a relatively nontoxic manner.
Mitchell S. Felder, M.D., the CEO and Chairman of the Board of NanoLogix,
Inc., stated, "I believe that this is a truly exciting and previously
unexplored therapeutic avenue for attacking leukemia, and related cancers.
It is our intention to greatly accelerate the development of this promising
methodology by partnering with a major university and pharmaceutical firm
in the oncology arena."
About NanoLogix, Inc.:
NanoLogix is an industry innovator in the research, development and
commercialization of nano-biotechnologies, applications and processes. The
Company owns or has the rights to 32 patented technologies. The Company is
currently focused on the production of hydrogen from agricultural
feedstock, industrial wastewater and municipal waste streams to create new
sources of energy. NanoLogix is presently operating a hydrogen bioreactor
at Welch's Food and has recently signed an agreement with the City of Erie
Wastewater Treatment Plant for a prototype bioreactor installation.
Additionally, NanoLogix develops and markets diagnostic test kits for use
in early detection of infectious human diseases such as cancer, cystic
fibrosis and AIDS, and owns a patent for the nontoxic induction of
apoptosis ('cell suicide') for the treatment of cancer. For more
information on the Company, visit http://www.nanologix.net.
This press release contains statements, which may constitute
"forward-looking statements" within the meaning of the Securities Act of
1933 and the Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Those statements include
statements regarding the intent, belief or current expectations of
NanoLogix, Inc., and members of its management as well as the assumptions
on which such statements are based. Prospective investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results
may differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or revise
forward-looking statements to reflect changed assumptions, the occurrence
of unanticipated events or changes to future operating results.